Inovio Pharmaceuticals Inc — Cash Flow (NASDAQ:INO) | MetaTrader

Open full chart

Financials

Overview 明細書 Statistics Dividends

Quarterly Annual

Cash from operating activities -177.98 M-215.71 M-216.22 M-124.37 M-104.08 M -88.92 M Cash from investing activities -58.8 M-175.34 M109.59 M87.36 M104.07 M 48.74 M Cash from financing activities 465.28 M211.5 M81.84 M5 M51.48 M 55.06 M Free cash flow -179.5 M-216.94 M-217.18 M-124.69 M-104.56 M -89.08 M

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc. is an American biotechnology company focused on the discovery, development, and commercialization of synthetic DNA products for treating cancers and infectious diseases. In April 2020, Inovio was among some 100 companies, academic centers, or research organizations developing a vaccine candidate for treating people infected with COVID-19, with more than 170 total vaccine candidates in development.

ニュース

Inovio、OppenheimerカンファレンスでINO-3107の戦略的見解を提示

INO-3107 At The Crossroads: FDA Review Drives Inovio's Upside And Risk (NASDAQ:INO)

Inovio Pharmaceuticals: Speculative Buy Thesis Hinges On INO-3107 (NASDAQ:INO)

ジェフリーズ、イノビオ株の保留評価を維持、FDA審査の不確実性の中で

Jefferies reiterates Hold on Inovio stock amid FDA review uncertainty

イノビオ・ファーマシューティカルズ株、FDA がINO-3107のBLAを受理も横ばい

Inovio Pharmaceuticals stock steady as FDA accepts BLA for INO-3107

イノビオ株、FDA迅速承認経路に疑問を呈し急落

Inovio stock tumbles after FDA questions accelerated approval path

INOVIOのRRP治療薬BLA、FDAが受理し2026年10月を目標日に設定

FDA accepts INOVIO’s BLA for RRP treatment, sets October 2026 target date

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 42%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Autolus Therapeutics (NASDAQ:AUTL), Brand Engagement Network (NASDAQ:BNAI)